QNCX — Quince Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $234.98m
- $226.21m
Annual income statement for Quince Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 78.9 | 90.3 | 52 | 34.7 | 57.3 |
| Operating Profit | -78.9 | -90.3 | -52 | -34.7 | -57.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -76.8 | -89.9 | -51.9 | -31.6 | -56.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -76.8 | -89.9 | -51.7 | -31.4 | -56.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -76.8 | -89.9 | -51.7 | -31.4 | -56.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -76.8 | -89.9 | -51.7 | -31.4 | -56.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.63 | -3.03 | -1.53 | -0.739 | -1.06 |